31. Consolidated companies as of 31 December 2020
Name of the subsidiary |
Country |
% voting right |
Change in % voting |
Biofocus DPI AG (liquidated) |
Switzerland |
0% |
(100%) |
Galapagos Biopharma Belgium BV |
Belgium |
100% |
- |
Galapagos Biopharma Netherlands B.V. |
The Netherlands |
100% |
- |
Galapagos Biopharma Spain S.L.U |
Spain |
100% |
- |
Galapagos Biopharma Italy S.r.l. |
Italy |
100% |
- |
Galapagos Biopharma Germany GmbH |
Germany |
100% |
- |
Galapagos Biotech Ltd. |
United Kingdom |
100% |
- |
Galapagos BV |
The Netherlands |
100% |
- |
Galapagos GmbH |
Switzerland |
100% |
- |
Galapagos, Inc. |
United States |
100% |
- |
Galapagos NV |
Belgium |
Parent company |
- |
Galapagos Real Estate Belgium BV |
Belgium |
100% |
- |
Galapagos Real Estate Netherlands B.V. |
The Netherlands |
100% |
- |
Galapagos SASU |
France |
100% |
- |
Fidelta d.o.o. |
Croatia |
100% |
- |
Xenometrix, Inc. in liquidation |
United States |
100% |
- |
In the course of 2020 we merged Galapagos Real Estate 2 BV with Galapagos Real Estate 1 BV, with the latter being the surviving entity whose company name changed into Galapagos Real Estate Belgium BV. Our dormant Swiss subsidiary BioFocus DPI AG was deconsolidated in 2020 and the final actions for its liquidation were completed in 2020. In 2021 solely its deregistration from the Swiss commercial register still needs to occur.
On 23 November 2020 we signed a share purchase agreement for the sale of our subsidiary Fidelta d.o.o. (Zagreb, Croatia). As we expect that the net assets associated with Fidelta d.o.o. will be recovered principally through a sale transaction rather than through continuing use, we have classified these assets and the associated liabilities as held for sale in our financial statements for the year ended 31 December 2020. On 4 January 2021 we closed the sale of our fee-for-service business Fidelta. Selvita S.A. acquired 100% of the outstanding shares in Fidelta.
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.